On the company's website it says: "According to a company release, the study involved 131 patients at nine medical centres in the USA and one in Israel. The stu

On the company's website it says: "According to a company release, the study involved 131 patients at nine medical centres in the USA and one in Israel. The study evaluated the safety and efficacy of the neuroAD Therapy System in comparison to placebo, following six weeks of treatment and six weeks of follow-up, using the cognitive and behavioural standard scales for the evaluation of patients with Alzheimer’s disease. The study’s positive outcomes confirm and extend the results of former studies conducted across the world with the neuroAD Therapy System. The detailed results of the study will be presented at the International Conference on Clinical Trials for Alzheimer’s Disease (CTAD; 8–10 December, San Diego, USA)."